ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,860.00
0.49%
S&P ASX All Technology
3,102.60
0.47%
Brent Oil
79.395
-0.61%
US Dollar vs AUD
1.51745
1.20%
Bitcoin
69,316.82
-2.05%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Cellectis Nom Eo 05 (ALCLS)

  7. Cellectis Nom Eo 05 (ALCLS) News

ALCLS

Cellectis Nom Eo 05 (ALCLS)

Cellectis Nom Eo 05
Date:
Sort by:
 Showing the most relevant articles for your search:EU:ALCLS
DateTimeSourceHeadlineSymbolCompany
06/06/202406:30GlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
06/06/202406:30GlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
05/06/202406:30GlobeNewswire Inc.Cellectis obtient la désignation de médicament orphelin pour son produit CAR T allogénique UCART22 pour les patients atteints de leucémie lymphoblastique aiguëEU:ALCLSCellectis Nom Eo 05
05/06/202406:30GlobeNewswire Inc.Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic LeukemiaEU:ALCLSCellectis Nom Eo 05
30/05/202406:30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
30/05/202406:30GlobeNewswire Inc.Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024EU:ALCLSCellectis Nom Eo 05
30/05/202406:30GlobeNewswire Inc.L’ Assemblée Générale Mixte de Cellectis se tiendra le 28 juin 2024EU:ALCLSCellectis Nom Eo 05
29/05/202406:30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024EU:ALCLSCellectis Nom Eo 05
29/05/202406:30GlobeNewswire Inc.Cellectis publie ses résultats financiers du premier trimestre 2024EU:ALCLSCellectis Nom Eo 05
28/05/202406:30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
28/05/202406:30GlobeNewswire Inc.Cellectis publiera ses résultats financiers du premier trimestre 2024 le 28 mai 2024EU:ALCLSCellectis Nom Eo 05
28/05/202406:30GlobeNewswire Inc.Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024EU:ALCLSCellectis Nom Eo 05
17/05/202406:30GlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
17/05/202406:30GlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
07/05/202406:30GlobeNewswire Inc.Monthly information on share capital and company voting rightsEU:ALCLSCellectis Nom Eo 05
07/05/202406:30GlobeNewswire Inc.Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:ALCLSCellectis Nom Eo 05
06/05/202416:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
06/05/202416:00GlobeNewswire Inc.Cellectis annonce la réalisation de l’investissement additionnel d’AstraZenecaEU:ALCLSCellectis Nom Eo 05
06/05/202416:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaEU:ALCLSCellectis Nom Eo 05
03/05/202406:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
03/05/202406:30GlobeNewswire Inc.Cellectis nomme Arthur Stril directeur financier par intérimEU:ALCLSCellectis Nom Eo 05
03/05/202406:30GlobeNewswire Inc.Cellectis Appoints Arthur Stril as Interim Chief Financial OfficerEU:ALCLSCellectis Nom Eo 05
30/04/202406:46GlobeNewswire Inc.Cellectis publie ses résultats financiers du quatrième trimestre 2023 et de l’exercice 2023 EU:ALCLSCellectis Nom Eo 05
30/04/202406:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
30/04/202406:46GlobeNewswire Inc.Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023EU:ALCLSCellectis Nom Eo 05
23/04/202406:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsEU:ALCLSCellectis Nom Eo 05
23/04/202406:30GlobeNewswire Inc.Cellectis présente de nouveaux procédés d’éditions par TALEN® permettant une insertion et une correction du génome très efficaces dans les cellules souches progénitrices et hématopoïétiques (CSPHs)EU:ALCLSCellectis Nom Eo 05
23/04/202406:30GlobeNewswire Inc.Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCsEU:ALCLSCellectis Nom Eo 05
11/04/202406:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsEU:ALCLSCellectis Nom Eo 05
11/04/202406:30GlobeNewswire Inc.Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCsEU:ALCLSCellectis Nom Eo 05
 Showing the most relevant articles for your search:EU:ALCLS

Your Recent History

ASX
WDC
Westfield
NYSE
VZ
Verizon Communications
ASX
NCM
Newcrest Mining
ASX
NAB
National Australia Bank
ASX
XTO
S&P ASX 100
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
ASX
XJO
S&P ASX 200
FX
AUDCAD
AUD vs CAD
ASX
MQG
Macquarie
ASX
QBE
QBE Insurance
NASDAQ
MSFT
Microsoft
ASX
WBC
Westpac Banking
ASX
WPL
Woodside Petroleum
ASX
XFL
S&P ASX 50
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved